Andrew Perkins
Overview
Explore the profile of Andrew Perkins including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
37
Citations
825
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Neale J, Cairns B, Gardiner K, Livingston W, McCarthy T, Perkins A
Addict Sci Clin Pract
. 2024 Dec;
19(1):89.
PMID: 39617936
Background: The therapeutic alliance is an important predictor of treatment outcomes but people who use alcohol and other drugs report mixed views of treatment providers. We analysed patients' accounts of...
2.
Harrison C, Mesa R, Talpaz M, Gupta V, Gerds A, Perkins A, et al.
Clin Lymphoma Myeloma Leuk
. 2024 Nov;
25(3):199-211.
PMID: 39516087
Purpose: Anemia is a cardinal feature of myelofibrosis often managed with red blood cell (RBC) transfusions, which may contribute to negative prognostic, quality-of-life, and healthcare-related economic impacts. The Janus kinase...
3.
Huang S, Reed C, Ilsley M, Magor G, Tallack M, Landsberg M, et al.
Nat Commun
. 2024 Aug;
15(1):7019.
PMID: 39147774
The SP/KLF family of transcription factors harbour three C-terminal C2H2 zinc fingers interspersed by two linkers which confers DNA-binding to a 9-10 bp motif. Mutations in KLF1, the founding member...
4.
Campbell E, Bonomo Y, Collins L, Norman A, ONeill H, Streitberg A, et al.
Clin Case Rep
. 2024 May;
12(5):e8740.
PMID: 38698873
Key Clinical Message: This case suggests using dual orexin receptor antagonists to treat alcohol use disorder and comorbid sleep disorders may be effective, commencing treatment in withdrawal and continuing it...
5.
Oh S, Verstovsek S, Gupta V, Platzbecker U, Devos T, Kiladjian J, et al.
EJHaem
. 2024 Feb;
5(1):105-116.
PMID: 38406514
Bone marrow fibrosis (BMF) is a pathological feature of myelofibrosis, with higher grades associated with poor prognosis. Limited data exist on the association between outcomes and BMF changes. We present...
6.
Neale J, Cairns B, Gardiner K, Livingston W, McCarthy T, Perkins A
Int J Drug Policy
. 2023 Dec;
123:104291.
PMID: 38071934
Background: There is limited provision of inpatient detoxification relative to other treatments for alcohol and other drug (AOD) use. This means people often need to wait prior to detoxifying. However,...
7.
Ng W, Erber W, Grigg A, Dunne K, Perkins A, Forsyth C, et al.
Pathology
. 2023 Dec;
56(1):75-80.
PMID: 38071156
The Philadelphia-negative myeloproliferative neoplasms (MPN) are a heterogeneous group of overlapping bone marrow disorders defined by characteristic peripheral blood counts and bone marrow morphological findings in conjunction with recurrent somatic...
8.
Willcox D, Trent R, Lyons N, Meldrum C, Kennedy P, Lee T, et al.
Aust Health Rev
. 2023 Oct;
47(6):631-633.
PMID: 37844625
NSW Health is implementing genomics as a mainstream component of clinical care. The strategic, holistic approach is considering infrastructure, data governance and management, workforce, education, service planning and delivery. This...
9.
Pemmaraju N, Garcia J, Perkins A, Harb J, Souers A, Werner M, et al.
Cancer
. 2023 Aug;
129(22):3535-3545.
PMID: 37584267
Myelofibrosis is a heterogeneous myeloproliferative neoplasm characterized by chronic inflammation, progressive bone marrow failure, and hepatosplenic extramedullary hematopoiesis. Treatments like Janus kinase inhibitor monotherapy (e.g., ruxolitinib) provide significant spleen and...
10.
Gerds A, Verstovsek S, Vannucchi A, Al-Ali H, Lavie D, Kuykendall A, et al.
Lancet Haematol
. 2023 Jul;
10(9):e735-e746.
PMID: 37517413
Background: The MOMENTUM study met all key endpoints at week 24, demonstrating symptom, spleen, and anaemia benefits with momelotinib versus danazol in patients with myelofibrosis. In this updated analysis, we...